UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.971-984

2021

Volltextzugriff (PDF)

Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study

PloS one, 2024-03, Vol.19 (3), p.e0299510-e0299510

2024

Volltextzugriff (PDF)

Non-invasive skin sampling detects systemically administered drugs in humans

PloS one, 2022-07, Vol.17 (7), p.e0271794-e0271794

2022

Volltextzugriff (PDF)

An untargeted metabolomics analysis of exogenous chemicals in human milk and transfer to the infant

Clinical and translational science, 2022-11, Vol.15 (11), p.2576-2582

2022

Volltextzugriff (PDF)

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans

Journal of clinical pharmacology, 2016-07, Vol.56 (S7), p.S82-S98

2016

Volltextzugriff (PDF)

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Clinical and translational science, 2020-09, Vol.13 (5), p.972-984

2020

Volltextzugriff (PDF)

Physicochemical properties determining drug detection in skin

Clinical and translational science, 2022-03, Vol.15 (3), p.761-770

2022

Volltextzugriff (PDF)

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping

Therapeutic drug monitoring, 2015-02, Vol.37 (1), p.84-89

2015

Volltextzugriff (PDF)

Mtor inhibitors associated with higher cardiovascular adverse events—A large population database analysis

Clinical transplantation, 2021-04, Vol.35 (4), p.e14228-n/a

2021

Volltextzugriff (PDF)

Chemical Proportionality within Molecular Networks

Analytical chemistry (Washington), 2021-09, Vol.93 (38), p.12833-12839

2021

Volltextzugriff (PDF)

Advancing Pharmacist Collaborative Care within Academic Health Systems

Pharmacy, 2019-10, Vol.7 (4), p.142

2019

Volltextzugriff (PDF)

Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Case reports in transplantation, 2018, Vol.2018, p.7410508-5

2018

Volltextzugriff (PDF)

Transfer of antibiotics and their metabolites in human milk: Implications for infant health and microbiota

Pharmacotherapy, 2023-05, Vol.43 (5), p.442-451

2023

Volltextzugriff (PDF)

Assessing Students’ Satisfaction with a Redesigned Pharmacology Course Series

American journal of pharmaceutical education, 2019-09, Vol.83 (7), p.6971-1463, Article 6971

2019

Volltextzugriff (PDF)

Initial Development toward Non-Invasive Drug Monitoring via Untargeted Mass Spectrometric Analysis of Human Skin

Analytical chemistry (Washington), 2019-07, Vol.91 (13), p.8062-8069

2019

Volltextzugriff (PDF)

National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation

Clinical transplantation, 2020-10, Vol.34 (10), p.e14037-n/a

2020

Volltextzugriff (PDF)

Computational Removal of Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter

Journal of the American Society for Mass Spectrometry, 2019-02, Vol.30 (2), p.268-277

2019

Volltextzugriff (PDF)

Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation

Pharmacogenomics, 2019-12, Vol.20 (18), p.1291-1302

2019

Volltextzugriff (PDF)

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

Journal of clinical pharmacology, 2018-09, Vol.58 (9), p.1205-1213

2018

Volltextzugriff (PDF)

Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults

Journal of clinical pharmacology, 2019-11, Vol.59 (11), p.1495-1504

2019

Volltextzugriff (PDF)

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes: A Need for Validation

Clinical pharmacokinetics, 2010-04, Vol.49 (4), p.223-237

2010

Volltextzugriff (PDF)

Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation

International journal of clinical pharmacology and therapeutics, 2012-07, Vol.50 (7), p.468-475

2012

Volltextzugriff (PDF)

Cost minimization of medicare part D prescription drug plan expenditures

The American journal of managed care, 2009-08, Vol.15 (8), p.545-553

2009

Volltextzugriff (PDF)

Telbivudine for the treatment of hepatitis B disease

Future virology, 2008-11, Vol.3 (6), p.517-527

2008

Volltextzugriff (PDF)

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

Journal of clinical pharmacology, 2002-04, Vol.42 (4), p.376-382

2002

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(44)
Berichte
(1)

Sprache

Englisch
(45)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability

Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study

Non-invasive skin sampling detects systemically administered drugs in humans

An untargeted metabolomics analysis of exogenous chemicals in human milk and transfer to the infant

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study

Physicochemical properties determining drug detection in skin

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping

Mtor inhibitors associated with higher cardiovascular adverse events—A large population database analysis

Chemical Proportionality within Molecular Networks

Advancing Pharmacist Collaborative Care within Academic Health Systems

Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Transfer of antibiotics and their metabolites in human milk: Implications for infant health and microbiota

Assessing Students’ Satisfaction with a Redesigned Pharmacology Course Series

Initial Development toward Non-Invasive Drug Monitoring via Untargeted Mass Spectrometric Analysis of Human Skin

National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation

Computational Removal of Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter

Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes: A Need for Validation

Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation

Cost minimization of medicare part D prescription drug plan expenditures

Telbivudine for the treatment of hepatitis B disease

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

Suchergebnisse filtern